Evommune officer granted 73,892 stock options
Evommune, Inc. reported that Chief of Development Operations Janice Suzann Drew received an employee stock option grant covering 73,892 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Evommune, Inc. reported that Chief of Development Operations Janice Suzann Drew received an employee stock option grant covering 73,892 shares of common stock. The options carry an exercise price of $26.77 per share and expire on April 15, 2036.
According to the vesting terms, one fourth of the options will vest on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments thereafter, contingent on continued service. Following this grant, the reporting person holds 73,892 stock options directly.
Insider Trade Summary
Grant/Award: 73,892 shares
Grant/Award
1 txn
Insider
Drew Janice Suzann
Role
Chief of Dev. Operations
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 73,892 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 73,892 contracts (Direct)
Footnotes (1)
- F1. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Option grant size: 73,892 options
Exercise price: $26.77 per share
Expiration date: April 15, 2036
+3 more
6 metrics
Option grant size
73,892 options
Employee stock option grant to Chief of Development Operations
Exercise price
$26.77 per share
Stock option exercise price for Evommune common stock
Expiration date
April 15, 2036
Option expiration for granted employee stock options
Post-transaction options held
73,892 options
Total options held directly after the grant
Initial vesting
25% after 1 year
One fourth vests on first anniversary of grant date
Ongoing vesting schedule
36 monthly installments
Remaining options vest in equal monthly tranches
Key Terms
Employee Stock Option, grant/award acquisition, vesting, Common Stock
4 terms
Employee Stock Option financial
""Employee Stock Option (Right to Buy)" granted to the officer"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
grant/award acquisition financial
"transaction_action is listed as "grant/award acquisition""
vesting financial
"shares subject to the option award shall vest on the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title is identified as "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Evommune (EVMN) report in this Form 4?
Evommune reported a stock option grant to its Chief of Development Operations. She received 73,892 employee stock options, giving her the right to buy common shares at a fixed exercise price, as part of her equity-based compensation package.
Who is the Evommune insider involved in this Form 4 filing?
The insider is Janice Suzann Drew, Evommune’s Chief of Development Operations. The filing shows she received a grant of stock options, reflecting compensation rather than an open-market purchase or sale of existing Evommune common shares.
How many Evommune stock options were granted to the officer?
The officer was granted 73,892 employee stock options. Each option represents the right to purchase one share of Evommune common stock, subject to vesting conditions and payment of the stated exercise price when exercised in the future.
What is the exercise price and expiration date of the Evommune options?
The options have an exercise price of $26.77 per share and expire on April 15, 2036. This means the holder can buy Evommune common stock at $26.77, once vested, any time before the April 2036 expiration date.
How do the Evommune stock options granted to the officer vest over time?
One fourth of the options vest on the first anniversary of the grant date. The remaining options vest in 36 equal monthly installments, provided the officer remains in continuous service with Evommune through each applicable vesting date.
What are the officer’s Evommune holdings after this stock option grant?
After the transaction, the officer directly holds 73,892 stock options. These options give her the potential to purchase Evommune common stock in the future, subject to vesting and the payment of the $26.77 per share exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates